At 1031 hours, the CNX Pharma index was up 0.52% or 67 points at 12,764, compared to a marginal 0.03% decline in the CNX Nifty.
Dr Reddy’s Laboratories is up 1.5% at Rs 3,813 after hitting a record high of Rs 3,785 on the BSE in intra-day trades. The company announced post market hours on Monday that it has launched Memantine hydrochloride tablets of 5 mg and 10 mg. The product is a therapeutic equivalent generic version of Namenda of Forest Laboratories LLC, a wholly owned subsidiary of Dublin-headquartered global pharmaceutical company Actavis PLC.
Namenda tablets brand had US sales of approximately $1.4 billion for the recent twelve months ending in May 2015, Dr Reddy's said quoting the IMS Health data. The drug is indicated for the treatment of moderate to severe dementia of Alzheimer's.
Aurobindo Pharma was up 1% at Rs 1,510, extending its previous day’s 3% gain on the BSE, after the company received final approval from the US Food and Drug Administration (UFDA) to produce and sell Flecainide Acetate Tablets -- used for regulating heart rate -- in the American market.
Other pharma stocks such as Elder Pharma, TTK Healthcare, Suven Life Sciences, Fortis Healthcare, Vivimed Laboratories, Aarti Drugs, Marksans Pharma and Claris Lifesciences were also up 2%-8% in an otherwise subdued market.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)